| |
| |
|
| Insider
Information: |
Bertrand William C Jr |
| Relationship: |
Chief Operating Officer |
| City: |
Gaithersburg |
| State: |
MD |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
246,444 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,426,046 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
246,444 |
|
|
| Total
Value |
$1,426,046 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
16
|
|
Stock
price went up :
|
1
|
5
|
| Stock
price went down : |
0
|
11
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
1.0
|
| Percentage
Gain/Loss : |
 20.5%
|
117.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Medimmune Inc |
MEDI |
Senior VP, General Cou... |
2007-06-01 |
0 |
|
0 |
Premium* |
|
|
Salix Pharmaceuticals Ltd |
SLXP |
See Remarks |
2015-04-01 |
0 |
2013-07-24 |
0 |
Premium* |
|
|
Infinity Pharmaceuticals Inc |
INFI |
Officer |
2015-10-19 |
7,500 |
|
0 |
Premium* |
|
|
Ardelyx Inc |
ARDX |
Director |
2023-06-15 |
218,743 |
2015-12-17 |
0 |
Premium* |
|
|
Adaptimmune Therapeutics PLC |
ADAP |
Chief Operating Officer |
2024-01-17 |
20,201 |
2019-01-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2024-01-17 |
4 |
S |
$0.67 |
$12,725 |
D/D |
(18,908) |
20,201 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2024-01-16 |
4 |
S |
$0.79 |
$3,698 |
D/D |
(4,681) |
7,023 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2024-01-12 |
4 |
S |
$0.85 |
$4,458 |
D/D |
(5,220) |
7,874 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2024-01-11 |
4 |
S |
$0.84 |
$3,354 |
D/D |
(4,009) |
6,104 |
0 |
% |
|
| ARDX |
Ardelyx Inc |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,581 |
218,743 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2023-01-17 |
4 |
S |
$1.86 |
$8,250 |
D/D |
(4,440) |
7,264 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2023-01-12 |
4 |
S |
$1.71 |
$8,484 |
D/D |
(4,973) |
8,121 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2023-01-11 |
4 |
S |
$1.75 |
$6,713 |
D/D |
(3,843) |
6,270 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2023-01-04 |
4 |
S |
$1.69 |
$6,071 |
D/D |
(3,584) |
5,781 |
0 |
% |
|
| ARDX |
Ardelyx Inc |
Director |
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
118,613 |
202,162 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2022-01-18 |
4 |
S |
$3.19 |
$13,942 |
D/D |
(4,368) |
7,336 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2022-01-12 |
4 |
S |
$3.54 |
$7,967 |
D/D |
(2,248) |
3,754 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2022-01-11 |
4 |
S |
$3.56 |
$13,409 |
D/D |
(3,770) |
6,343 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2022-01-04 |
4 |
S |
$4.06 |
$14,184 |
D/D |
(3,490) |
5,873 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2021-07-02 |
4 |
S |
$4.26 |
$18,659 |
D/D |
(4,375) |
7,329 |
0 |
% |
|
| ARDX |
Ardelyx Inc |
Director |
– • – |
2021-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,891 |
83,549 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2021-01-12 |
4 |
S |
$6.15 |
$13,744 |
D/D |
(2,234) |
3,768 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2021-01-04 |
4 |
S |
$5.33 |
$18,642 |
D/D |
(3,499) |
5,864 |
0 |
% |
|
| ARDX |
Ardelyx Inc |
Director |
– • – |
2020-12-14 |
4 |
A |
$7.08 |
$106,256 |
D/D |
15,000 |
74,658 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2020-12-14 |
4 |
B |
$0.69 |
$143,824 |
D/D |
207,000 |
284,808 |
2.74 |
% |
|
| ARDX |
Ardelyx Inc |
Director |
– • – |
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
7,523 |
59,658 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2020-01-14 |
4 |
S |
$5.13 |
$12,308 |
D/D |
(2,397) |
3,605 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2020-01-06 |
4 |
S |
$1.20 |
$4,477 |
D/D |
(3,731) |
5,632 |
0 |
% |
|
| ARDX |
Ardelyx Inc |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
18,248 |
52,135 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Operating Officer |
• – – |
2019-01-14 |
4 |
S |
$5.37 |
$12,194 |
D/D |
(2,271) |
3,731 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
